Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.65 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.57 |
| ▸ | PPARA | Q07869 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6641305 | 0.98 | HDAC1 (0.62) | HDAC1HDAC2KCNA3HDAC3HDAC4 | |
| SCHEMBL351889 | 0.92 | KCNA3 (0.58) | HDAC1HDAC2KCNA3 | |
| SCHEMBL1308374 | 0.86 | CYP1A2 (0.58) | HDAC1HDAC2KCNA3 | |
| SCHEMBL7367452 | 0.86 | HDAC1 (0.69) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL25228768 | 0.85 | PPARA (0.72) | HDAC1HDAC2KCNA3HDAC3HDAC4 | |
| SCHEMBL11616532 | 0.85 | PPARA (0.72) | HDAC1HDAC2KCNA3HDAC3HDAC4 | |
| SCHEMBL712775 | 0.85 | PPARA (0.72) | HDAC1HDAC2KCNA3HDAC3HDAC4 | |
| SCHEMBL6342300 | 0.85 | PPARA (0.72) | HDAC1HDAC2KCNA3HDAC3HDAC4 | |
| SCHEMBL503552 | 0.85 | PPARA (0.72) | HDAC1HDAC2KCNA3HDAC3HDAC4 | |
| SCHEMBL1008297 | 0.85 | PPARA (0.72) | HDAC1HDAC2KCNA3HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE41226-E1 | Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-04-13 | — | — | US | disclosed |
| US-RE40861-E1 | Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase | Sigma-Tau Industrie Farmaceutiche Reunite S.p.A. (IT) | 2009-07-21 | — | — | US | disclosed |
| EP-1077925-B1 | COMPOUNDS HAVING REVERSIBLE INHIBITING ACTIVITY OF CARNITINE PALMITOYL-TRANSFERASE | SIGMA TAU IND FARMACEUTI (IT) | 2004-09-15 | — | — | EP | disclosed |
| US-20020161030-A1 | Sulpur derivatives containing a retroamide bond as inhibitors of endothelin-converting enzymes | HOECHST MARION ROUSSEL | 2002-10-31 | — | — | US | disclosed |
| US-6444701-B1 | TREATING HYPERGLYCEMIA, DIABETES AND PATHOLOGIES RELATED THERETO, HEART FAILURE, ISCHEMIA. | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-09-03 | — | — | US | disclosed |
| US-6420341-B1 | TREATING VASOCONSTRICTOR AND HYPERTENSION EFFECTS IN WARM-BLOODED ANIMALS | AVENTIS PHARMA S.A. (FR) | 2002-07-16 | — | — | US | disclosed |
| US-20020052348-A1 | Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. | 2002-05-02 | — | — | US | disclosed |
| US-6369073-B1 | HYPERGLYCEMIA, DIABETES, HEART FAILURE, ISCHEMIA | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052348-A1 | Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase | CPT1A, CPT1B, CPT2 | HDAC1 72/4885HDAC2 406/4885KCNA3 2568/4885 |
| US-20020161030-A1 | Sulpur derivatives containing a retroamide bond as inhibitors of endothelin-converting enzymes | EDNRA, ECE1, EDNRB | HDAC1 3098/4885HDAC2 3395/4885KCNA3 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.